No recommendation
No news or research item is a personal recommendation to deal. Hargreaves Lansdown may not share ShareCast's (powered by Digital Look) views.
(Sharecast News) - Shares in Moderna tumbled 11% in pre-market trading on Thursday, after the US biotech detailed plans to cut its research budget by more than $1bn.
The Nasdaq-listed firm said it would focus on ten product approvals through 2027, including a next-generation Covid vaccine and combined 'flu and Covid jab.
But it will also discontinue five programmes in its pipeline, as it looks to cut research and development expenses by $1.1bn by 2027, to around $3.6bn-$3.8bn.
"Moderna's broad clinical success and recent commercial challenges necessitate a more selective and paced approach to its R&D investment," the firm said at an annual investor day.
Stephane Bancel, chief executive, said: "Our demonstrated probability of success in R&D has been higher than industry standards at every stage of development.
"The size of our late-stage pipeline combined with the challenge of launching products means we must now focus on delivering these ten products to patients, slow down the pace of new R&D investment and build out commercial business."
Moderna currently has five respiratory vaccines with positive phase 3 results, and expects to submit three for approval this year.
It is forecasting 2025 revenues to come in between $2.5bnd and $3.5bn. For 2026-28, it predicated a compounded annual growth rate of more than 25%, driven by new product launches.
The value of investments can go down in value as well as up, so you could get back less than you invest. It is therefore important that you understand the risks and commitments. This website is not personal advice based on your circumstances. So you can make informed decisions for yourself we aim to provide you with the best information, best service and best prices. If you are unsure about the suitability of an investment please contact us for advice.